Hearing and Other Neurologic Problems.

[1]  G. Reaman,et al.  Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. , 2019, The Lancet. Child & adolescent health.

[2]  A. E. Hoetink,et al.  Tinnitus during and after childhood cancer: A systematic review. , 2019, Critical reviews in oncology/hematology.

[3]  B. Carleton,et al.  A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy , 2019, PloS one.

[4]  A. Uitterlinden,et al.  Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study , 2018, JMIR research protocols.

[5]  Int Guideline Harmonization Grp.  Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium , 2019 .

[6]  K. Knight,et al.  Ototoxicity monitoring in children treated with platinum chemotherapy , 2018, International journal of audiology.

[7]  K. Johnston,et al.  Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes , 2018, JAMA neurology.

[8]  B. Morland,et al.  Sodium Thiosulfate for Protection from Cisplatin‐Induced Hearing Loss , 2018, The New England journal of medicine.

[9]  A. Uitterlinden,et al.  The influence of genetic variation on late toxicities in childhood cancer survivors: A review. , 2018, Critical reviews in oncology/hematology.

[10]  Elizabeth M. Wells,et al.  Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report , 2018, Neuro-oncology.

[11]  M. Hall,et al.  Cisplatin is retained in the cochlea indefinitely following chemotherapy , 2017, Nature Communications.

[12]  B. Pollock,et al.  Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[13]  A. am Zehnhoff-Dinnesen,et al.  Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. , 2016, European journal of cancer.

[14]  M. Farrar,et al.  Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. , 2016, Cancer treatment reviews.

[15]  Shaum P. Bhagat,et al.  Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Dreschler,et al.  Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long‐term follow‐up study , 2016, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[17]  W. Landier.  Ototoxicity and cancer therapy , 2016, Cancer.

[18]  E. C. van Dalen,et al.  Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. , 2016, The Cochrane database of systematic reviews.

[19]  G. de Castro,et al.  Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients. , 2015, Discovery medicine.

[20]  M. Chintagumpala,et al.  Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss , 2015, Nature Genetics.

[21]  T. Merchant,et al.  Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. , 2014, Neuro-oncology.

[22]  Nancy J Cox,et al.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. , 2014, Journal of the National Cancer Institute.

[23]  S. Bhatia,et al.  Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Saif,et al.  Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. , 2013, JOP : Journal of the pancreas.

[25]  R. Riccardi,et al.  Platinum compounds in children with cancer: toxicity and clinical management , 2013, Anti-cancer drugs.

[26]  S. Daniel,et al.  Characteristics of radiation‐induced sensorineural hearing loss in head and neck cancer: A systematic review , 2013, Head & neck.

[27]  A. am Zehnhoff-Dinnesen,et al.  Understanding platinum-induced ototoxicity. , 2013, Trends in pharmacological sciences.

[28]  Carmen L. Wilson,et al.  Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. , 2013, Archives of physical medicine and rehabilitation.

[29]  Khoi D. Than,et al.  Durability of hearing preservation after microsurgical treatment of vestibular schwannoma using the middle cranial fossa approach. , 2013, Journal of neurosurgery.

[30]  C. Lau,et al.  Glutathione S‐transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma , 2013, Pediatric blood & cancer.

[31]  F. Zeng.  An active loudness model suggesting tinnitus as increased central noise and hyperacusis as increased nonlinear gain , 2013, Hearing Research.

[32]  A. Nitz,et al.  Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. , 2013, Oncology letters.

[33]  R. Salvi,et al.  Review: Ototoxic Characteristics of Platinum Antitumor Drugs , 2012, Anatomical record.

[34]  J. Schacht,et al.  Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention , 2012, Anatomical record.

[35]  P. Steyger,et al.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Finlay,et al.  Hearing loss among survivors of childhood brain tumors treated with an irradiation‐sparing approach , 2012, Pediatric blood & cancer.

[37]  Daniel J. Guillaume,et al.  Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. , 2012, Journal of neurosurgery. Pediatrics.

[38]  R. Craver,et al.  Cisplatin and cranial irradiation-related hearing loss in children. , 2012, The Ochsner journal.

[39]  P. Allen,et al.  Radiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[40]  Mirela V. Simon.  Neurophysiologic Intraoperative Monitoring of the Vestibulocochlear Nerve , 2011, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[41]  S. Bhatia.  Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[42]  L. Rybak,et al.  Pharmacogenomics of cisplatin-induced ototoxicity. , 2011, Pharmacogenomics.

[43]  M. Kelley,et al.  Development of tonotopy in the auditory periphery , 2011, Hearing Research.

[44]  T. Merchant,et al.  Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group , 2010, Pediatrics.

[45]  E. Neuwelt,et al.  Critical need for international consensus on ototoxicity assessment criteria. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Kay W Chang,et al.  Practical grading system for evaluating cisplatin ototoxicity in children. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Rybak,et al.  Vestibular and Auditory Ototoxicity , 2010 .

[48]  A. Pappo,et al.  Amifostine does not prevent platinum‐induced hearing loss associated with the treatment of children with hepatoblastoma , 2009, Cancer.

[49]  M. Hayden,et al.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy , 2009, Nature Genetics.

[50]  L. Rybak,et al.  Cisplatin ototoxicity and protection: clinical and experimental studies. , 2009, The Tohoku journal of experimental medicine.

[51]  J. Benítez,et al.  Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients , 2009, The Pharmacogenomics Journal.

[52]  B. Fligor,et al.  Ototoxicity in children treated for osteosarcoma , 2009, Pediatric blood & cancer.

[53]  T. Merchant,et al.  Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. , 2008, International journal of radiation oncology, biology, physics.

[54]  Uwe Oelfke,et al.  Proton versus photon radiotherapy for common pediatric brain tumors: Comparison of models of dose characteristics and their relationship to cognitive function , 2008, Pediatric blood & cancer.

[55]  A. King,et al.  Hearing Loss in Pediatric Oncology Patients Receiving Carboplatin-containing Regimens , 2008, Journal of pediatric hematology/oncology.

[56]  K. Matthay,et al.  Hearing Loss, Quality of Life, and Academic Problems in Long-term Neuroblastoma Survivors: A Report From the Children's Oncology Group , 2007, Pediatrics.

[57]  K. Hirose,et al.  Aminoglycoside ototoxicity , 2007, Current opinion in otolaryngology & head and neck surgery.

[58]  K. Knight,et al.  Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  L. Rybak,et al.  Mechanisms of cisplatin-induced ototoxicity and prevention , 2007, Hearing Research.

[60]  X. Bu,et al.  Mitochondrial 12S rRNA A827G mutation is involved in the genetic susceptibility to aminoglycoside ototoxicity. , 2006, Biochemical and biophysical research communications.

[61]  N. Cheung,et al.  Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma , 2006, Cancer.

[62]  A. Moll,et al.  Assessment of hearing in very young children receiving carboplatin for retinoblastoma. , 2006, European journal of cancer.

[63]  Abha A. Gupta,et al.  Low Incidence of Ototoxicity With Continuous Infusion of Cisplatin in the Treatment of Pediatric Germ Cell Tumors , 2006, Journal of pediatric hematology/oncology.

[64]  D. Deuster,et al.  Die „Münsteraner Klassifikation“ , 2007, HNO.

[65]  K. Knight,et al.  Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W. London,et al.  Amifostine does not protect against the ototoxicity of high‐dose cisplatin combined with etoposide and bleomycin in pediatric germ‐cell tumors , 2005, Cancer.

[67]  S. Bielack,et al.  Cisplatin-Induced Ototoxicity in Osteosarcoma Patients: A Report from the Late Effects Surveillance System , 2005, Cancer investigation.

[68]  J. Silber,et al.  Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. , 2004, European journal of cancer.

[69]  L. Dupuis,et al.  Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study , 2004, Pediatric blood & cancer.

[70]  Mary Pat Moeller,et al.  The importance of high-frequency audibility in the speech and language development of children with hearing loss. , 2004, Archives of otolaryngology--head & neck surgery.

[71]  T. Merchant,et al.  Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. , 2002, International journal of radiation oncology, biology, physics.

[72]  Y. Young,et al.  Mechanism of Hearing Loss in Irradiated Ears: A Long-Term Longitudinal Study , 2001, The Annals of otology, rhinology, and laryngology.

[73]  M. Hudson,et al.  Late effects of treatment for germ cell tumors during childhood and adolescence. , 1999, Journal of pediatric hematology/oncology.

[74]  M. J. Osberger,et al.  Management of the child with sensorineural hearing loss. Medical, surgical, hearing aids, cochlear implants. , 1999, Pediatric clinics of North America.

[75]  J. Moore,et al.  The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. , 1999, Pediatric clinics of North America.

[76]  R. Parker,et al.  Children with Minimal Sensorineural Hearing Loss: Prevalence, Educational Performance, and Functional Status , 1998, Ear and hearing.

[77]  L. Rybak,et al.  Ototoxicity of loop diuretics. , 1993, Otolaryngologic clinics of North America.

[78]  P. Roberson,et al.  Ifosfamide and exacerbation of cisplatin-induced hearing loss , 1993, The Lancet.

[79]  C. R. Pinkerton,et al.  Cisplatin ototoxicity in children: a practical grading system. , 1991, Medical and pediatric oncology.

[80]  M. Gratton,et al.  Potentiation of cisplatin ototoxicity by noise. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  M. Schell,et al.  Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R A Bentler,et al.  Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. , 1986, The Journal of speech and hearing disorders.

[83]  A. Green,et al.  Hearing loss in children receiving cisplatin chemotherapy. , 1983, The Journal of pediatrics.

[84]  P. M. Shenoi.  Ototoxicity , 1973 .